Welcome to our dedicated page for Aptose Bioscienc news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Bioscienc stock.
Aptose Biosciences Inc (APTO) is a clinical-stage biotechnology company pioneering precision therapies for hematologic malignancies. This page serves as the definitive source for verified news and scientific updates related to APTO's innovative oncology pipeline.
Key resources include: Press releases on clinical trial progress, regulatory milestones, partnership announcements with pharmaceutical collaborators, and analyses of treatment mechanisms. Investors will find essential updates on the company's small molecule inhibitors and combination therapy developments targeting AML and high-risk MDS.
Our news collection enables: Tracking of APTO's progress in genetic-guided therapies, monitoring of FDA interactions, and insights into strategic collaborations advancing personalized cancer treatments. Content is curated to meet investor and researcher needs without promotional bias.
Bookmark this page for real-time updates on APTO's scientific advancements and corporate developments. Always consult official filings for investment decisions.
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) announced the adjournment of its special meeting of shareholders due to lack of quorum. The meeting, originally scheduled for August 15, 2024, has been postponed to September 5, 2024, at 1 p.m. ET. At the time of adjournment, proxies submitted represented only 32.76% of the company's outstanding common shares, falling short of the required 33.33% quorum.
Despite the lack of quorum, the company reports that based on proxy votes cast to date, all resolutions currently have the requisite levels of shareholder support. The board of directors believes that approving all matters outlined in the July 11, 2024 proxy statement is in the best interests of the company and its shareholders. The deadline for proxy submissions has been extended to September 4, 2024, at 1 p.m. ET.
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) reported financial results for Q2 2024 and provided a corporate update. Key highlights include:
1. FDA approval for tuspetinib triplet therapy protocol with venetoclax and azacitidine for newly diagnosed AML patients
2. Abstract submission to ASH 2024 for TUS+VEN+AZA triplet therapy
3. Nasdaq deficiency notice received for minimum bid price requirement
4. Q2 2024 net loss of $7.3 million, down from $14.1 million in Q2 2023
5. Cash position of $8.3 million as of June 30, 2024, expected to fund operations through August 2024
6. Research and development expenses decreased to $4.4 million in Q2 2024 from $10.6 million in Q2 2023
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, has received a deficiency notice from Nasdaq due to its stock price falling below the $1.00 minimum bid requirement for 30 consecutive business days. The company has until January 10, 2025, to regain compliance by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days. This notice does not immediately affect Aptose's Nasdaq listing, and its shares continue to trade on both Nasdaq and the Toronto Stock Exchange. If compliance is not achieved by the deadline, Aptose may be granted an additional 180-day period to meet the requirement. The company is monitoring the situation and considering options to address the deficiency.
Aptose Biosciences, a clinical-stage oncology company, announced the results of its annual and special meeting of shareholders held on June 18, 2024. Shareholders representing 49.67% of common shares participated in the voting. All nominees listed in the May 14, 2024 proxy statement were re-elected as Directors, including Carol G. Ashe, Denis Burger, Erich Platzer, William G. Rice, Bernd Seizinger, Mark D. Vincent, and Warren Whitehead. Shareholders also approved the re-appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2024.
Additional resolutions passed include an advisory vote on executive compensation, the potential issuance of common shares to warrant holders exceeding 19.99% of outstanding shares under Nasdaq rules, and an adjournment resolution to permit further solicitation of proxies if needed. Complete voting details will be available on SEDAR+ and EDGAR.
Aptose Biosciences presented clinical and preclinical findings on Tuspetinib (TUS) at the European Hematology Association (EHA) 2024 Hybrid Congress.
TUS, both as monotherapy and combined with Venetoclax (VEN), demonstrated broad clinical activity and strong safety data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) patients. The APTIVATE Phase 1/2 trial showed that TUS targets multiple kinases and maintains efficacy even in patients with adverse genetic mutations.
The company announced the initiation of a new triplet therapy trial combining TUS, VEN, and Azacitidine (AZA) for newly diagnosed AML patients.
Preclinical studies indicated that TUS targets VEN resistance mechanisms and retains activity against VEN-resistant AML cells.
Aptose aims to enhance treatment for newly diagnosed AML patients, showing promise in safety and efficacy. These findings highlight TUS's potential in overcoming VEN resistance and treating diverse genetic AML subgroups.
Aptose Biosciences announced the closing of a $4.43 million registered direct offering priced at-the-market under Nasdaq rules. The offering included 3,855,000 common shares at $1.15 per share. Concurrently, unregistered series A and B warrants were issued to purchase up to 3,855,000 common shares each at $1.15 per share. Series A warrants expire five years from shareholder approval, while series B warrants expire in eighteen months. Gross proceeds were approximately $4.43 million before fees and expenses. Funds will be used for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent.
Aptose Biosciences announced a registered direct offering priced at-the-market under Nasdaq rules, issuing 3,855,000 shares at $1.15 per share, raising approximately $4.43 million. In a concurrent private placement, unregistered series A and B warrants for 3,855,000 shares each were issued, exercisable at $1.15 per share. Series A warrants expire five years from shareholder approval, and series B warrants expire eighteen months from approval. The offering closes around June 3, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. Proceeds will be used for working capital and general corporate purposes.
Aptose Biosciences reported its Q1 2024 financial results and provided an update on its clinical-stage activities. The company is developing tuspetinib for AML treatment and has advanced it to a triplet therapy protocol with venetoclax and a hypomethylating agent, which has been submitted to the FDA and is being activated at clinical sites. Initial data from this study are expected by year-end.
Financially, Aptose reported a net loss of $9.6 million ($0.73 per share) for Q1 2024, an improvement from a $13.7 million loss ($2.22 per share) in the same period last year. Operating expenses decreased to $9.76 million from $14.1 million, and cash reserves were $9.3 million.
Aptose also highlighted upcoming milestones, including clinical trial data releases and triplet therapy studies. The company addressed Nasdaq compliance issues, regaining compliance with one rule and submitting a plan to address another.
Aptose Biosciences Inc. will report financial results for the first quarter of 2024 and provide a corporate update on May 14, 2024. The Chief Medical Officer will discuss the clinical strategy for advancing the lead asset tuspetinib in a triplet drug combination for the treatment of newly diagnosed AML patients.